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Performance and Carcass Characteristics
Zachary E. Carlson
Galen E. Erickson
Bill D. Dicke
Marshall N. Streeter
Summary and Implications
A commercial feedlot trial examined
effects of two implant strategies (Revalor-IH
on d 1 and re-implanted with Revalor-200
on d 101 or Revalor-XH on d 1) on growth
performance and carcass characteristics of
heifers fed 183 days. There were no differences between implant strategies for final body
weight, dry matter intake, and average daily
gain. Heifers implanted with the combination
IH/200 treatment had improved carcassadjusted feed conversion, greater LM area,
and lower calculated yield grade compared
to heifers implanted with XH. The response
in growth performance between the two
implant strategies suggests that the partiallycoated Revalor-XH implant can be used in
place of a more aggressive implant strategy
when heifers are fed to similar days.

Introduction
Heifers given increased trenbolone
acetate and estradiol tend to respond
with increased growth performance and
hot carcass weight. Heifers typically have
reduced growth performance compared
to steers due to increased fat deposition at
the same age. To improve growth performance of heifers, feedlots may utilize
aggressive implant protocols. Implanting once at the beginning of the feeding
period with a long-lasting, delayed-release
implant (Revalor-XH) may reduce potential stressors. The objective of this study
was to evaluate implanting heifers with a
partially coated Revalor-XH implant on d
1 compared to a more aggressive implant
strategy of Revalor-IH on d 1 followed by
Revalor-200 at a target of 80 d on terminal
© The Board Regents of the University of
Nebraska. All rights reserved.

implant. Finishing heifer performance and
carcass characteristics were measured.

Procedure
Crossbred heifers [n = 870; initial body
weight (BW) = 710; SD = 19.6 lb] were utilized in a finishing study conducted at HiGain Feedlot near Farnam, NE. The study
had a generalized randomized block design
with three blocks and two replications per
block. Heifers were sourced from Nebraska (two replications), North Dakota and
Montana (two replications), and Canada (2
replications). Heifers were fed for an average of 183 d (range 181–184 d) from May
2018 to November 2018. Treatments were:
Revalor-IH on d 1 (80 mg trenbalone acetate (TBA)/8 mg estradiol (E2), noncoated,
Merck Animal Health DeSoto, KS) and reimplanted with Revalor-200 on d 101 (200
mg TBA/20 mg E2, noncoated (IH/200),
Merck Animal Health) or Revalor-XH on d
1 (200 mg TBA/20 mg E2, partially coated
(XH); Merck Animal Health). Revalor-XH
contains four uncoated pellets (80 mg TBA
and 8 mg E2) for immediate release and six
coated pellets (120 mg TBA and 12 mg E2)
to release approximately 70 to 80 d after
implanting.
Heifers were randomly assigned to
pen (n = 12) by sorting every two heifers
into one of two pens within replication
prior to processing. Heifers were enrolled
in the study over two days. Heifers were
processed, pen weighed, and assigned to
treatment in a single event. Animals were
blocked based on origin source. Each block
contained an equal number of pens per
treatment. Pens were assigned randomly to
treatment with 6 pens per treatment and
an average of 73 animals per pen. Prior
to enrollment, all heifers were checked
for pregnancy. If pregnant, heifers were
removed from the pool of qualified animals. At processing, heifers received their
assigned implant, vaccine for protection
against bovine rhinotracheitis virus and
bovine viral diarrhea types one and two
viruses (Bovi-shield Gold 5; Zoetis, Flor-

ham Park, NJ), external parasite control via
dosing with 7 cc of moxidectin (Cydectin,
Bayer Animal Health, Germany), and
internal parasite control via drenching with
17 cc of fenbendazole (Safe-Guard, Merck)
oral suspension. Implants were placed in
the middle-third of the ear under the skin.
Heifers assigned to IH/200 treatment were
re-implanted 101 d after initial implanting.
At reimplant, all implants were placed in
the opposite ear of the initial implant.
Cattle were housed in open lots, with
similar square feet allocated per animal
across all pens, and ad libitum access to
water and feed. Diets were constant across
all treatments. All animals were adapted
to a common finishing diet over a 27-d
step up period consisting of four adaption diets. The finishing ration consisted
of 65.3% steam-flaked corn, 18.0% wet
distillers grains plus solubles, 4.5% mixed
hay, 5.5% corn silage, 1.7% tallow, and
5.0% supplement (DM basis). Supplement
was delivered daily via micro machine and
formulated to provide 30 g/ton DM of Rumensin (Elanco Animal Health), 8.9 g/ton
DM Tylan (Elanco Animal Health), 0.45
mg/hd/d of melengestrol acetate (MGA,
Zoestis) and 250 mg/hd/d DM of Optaflexx (Elanco Animal Health). The nutrient
composition of the finishing diet contained
14.6% crude protein, 6.6% crude fat, 1.04
Mcal/lb NEm, 0.72 Mcal/lb NEg, 0.7% Ca,
0.4% P, 0.7% K, and 0.2% S (DM basis).
Optaflexx was targeted to be fed for 29 d at
the end of the feeding period with a two d
withdraw prior to slaughter. Diet samples
were taken monthly and sent to a commercial laboratory (Servi-Tech Laboratories,
Hastings, NE) for feed composition (DM,
CP, NEm, NEg, Ca, P, K, and S). Weekly
feed ingredient samples were taken to
determine DM on site.
Cattle were scheduled for slaughter at
approximately 183 d (range 181–184 d)
on feed. Cattle were pen weighed prior to
loading onto the truck to be shipped. Cattle
were harvested at varying days on feed.
Replications one and two were harvested
at 181 days on feed and replications three,
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Table 1. Performance and carcass characteristics of heifers implanted with Revalor-XH or
Revalor-IH/200
Treatment1
Item

Rev-IH/200

Rev-XH

Head Count

435

435

Days on Feed

183

183

SEM

F-Test

—

—

—

—

Animals Removed, %

3.21

2.59

0.901

0.64

Death Loss, %

1.15

0.95

0.509

0.79

Live Performance
Initial BW, lb

713

708

3.3

0.36

Final BW2, lb

1393

1385

6.8

0.43

DMI, lb/d

0.18

0.33

ADG, lb

23.9
3.72

24.2
3.70

0.027

0.62

F:G

6.45

6.54

—

0.23

7.3

0.21

Carcass-Adjusted Performance
Final BW3, lb

1394

1380

ADG, lb

3.73

3.67

0.026

0.17

F:G

6.41

6.58

—

0.03

4.7

0.22

Carcass Characteristics
HCW, lb

880

871

Dressing, %

63.14

62.87

0.17

0.28

LM area, in2

13.7

13.0

0.14

<0.01

5.6

0.11

Marbling4

512

497

12th rib fat, in

0.75

0.74

0.009

0.32

Calculated YG5

3.75

3.89

0.025

<0.01

1

Treatments included: 1) Revalor-IH on d 1 (80 mg trenbalone acetate (TBA)/8 mg estradiol (E2), noncoated, Merck Animal
Health DeSoto, KS) and re-implanted with Revalor-200 on d 101 (200 mg TBA/20 mg E2, noncoated (IH/200), Merck Animal
Health); 2) Revalor-XH on d 1 (200 mg TBA/20 mg E2, partially coated (XH); Merck Animal Health). Revalor-XH contains
four uncoated pellets (80 mg TBA and 8 mg E2) for immediate release and six coated pellets (120 mg TBA and 12 mg E2) to
release approximately 70 to 80 d after implanting.

2

Final BW is the average pen weight shrunk four percent. Subsequent ADG and F:G are calculated from shrunk final BW.

disease, foot rot, or body injury. No differences (P > 0.64; Table 1) were observed
between implant treatments for percent
removed and mortality.
There were no differences (P > 0.23)
in live final BW, dry matter intake (DMI),
average daily gain (ADG), and feed conversion (F:G) due to implant treatment. There
were no differences (P > 0.17) in carcassadjusted final BW and ADG among implant
treatments. Although not significant,
carcass-adjusted ADG was 1.63% greater
for heifers implanted with the combination
IH/200 compared to heifers implanted
with XH. Carcass-adjusted feed conversion
improved 2.58% (P = 0.03) for heifers given
IH/200 compared to heifers implanted with
XH.
There were no differences (P > 0.22)
in HCW, dressing percent, and 12th rib fat
thickness among treatments. Heifers implanted with IH/200 had greater (P = 0.01)
LM area compared to heifers implanted
with XH. Calculated yield grade was greater
(P = 0.01) for heifers given XH compared
to heifers implanted with IH/200. The
distribution of USDA yield grades tended
to be significantly different (P = 0.08; Table
2) among treatments. The distribution of
USDA quality grades was not different (P =
0.35) among treatments.

Conclusion

3

Carcass-adjusted final BW was determined by dividing average HCW per treatment by the average dressing percent of 63.01%.

4

USDA marbling scores. 400 = small, 500 = modest, 600 = moderate.

5

th

2

YG = 2.50 + (2.5 * 12 -rib fat depth, in) + (0.2 * 3.0 KPH fat, %) + (0.0038 * HCW, lbs)—(0.32 * LM area, in ) where KPH fat
was assumed to be 3.0 %.

four, five, and six were harvested at 184
days on feed. All heifers were harvested at
a commercial abattoir (JBS Swift and Co.,
Grand Island, NE). Individual HCW was
collected at slaughter. Following a 24-hr
chill, 12th-rib fat depth, LM area, marbling,
USDA quality grade, and USDA yield grade
were collected from camera data. There
were 11 carcasses removed from analysis
due to missing carcass data or misidentified
individual animal IDs. Therefore, carcass
data were analyzed with 414 and 420 heifers
in IH/200 and XH, respectively.
Performance and carcass data were
analyzed as a generalized randomized
block design using the MIXED procedure
of SAS (9.4, SAS Institute Inc., Cary, NC).
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Treatment and block were fixed effects.
The model included implant treatment
and block. Pen was the experimental unit.
Treatment averages were calculated using
the LSMEANS option of SAS. Frequency
data, such as USDA quality grade and yield
grade distributions, were analyzed using the
GLIMMIX procedure of SAS using a multinomial approach. Treatment differences
were significant at α ≤ 0.05 and tendencies
were discussed when 0.05 ≤ α ≤ 0.10.

Results
There were nine heifers that died over
the course of the study. Sixteen heifers were
removed from the trial due to respiratory

Overall, growth performance and carcass characteristics were relatively similar
among IH/200 and XH treatments. However, heifers given IH/200 had improved
carcass-adjusted feed efficiency, LM area,
and calculated yield grade compared to
heifers given XH. These data suggest when
heifers are fed the same number of days the
combination IH/200 implants can improve
animal performance compared to the XH
implant.
Zachary E. Carlson, graduate student
Galen E. Erickson, professor, Animal
Science, University of Nebraska, Lincoln,
NE
Bill D. Dicke, Dicke Consulting, LLC,
Lincoln, NE
Marshall N. Streeter, Merck Animal Health,
De Soto, KS

Table 2. Quality grade and yield grade distribution of heifers fed for an average of 183 d implanted
with Revalor-IH/200 or Revalor-XH
Treatment1
Item

Rev-IH/200

Rev-XH

P-Values

4.9

4.7

0.35

Upper Choice

45.2

43.3

Choice

35.8

40.4

Select

13.8

11.2

0.2

0.3

YG 1

0.9

0.9

YG 2

12.1

5.4

YG 3

38.6

40.9

YG 4

39.2

44.1

YG 5

9.1

8.7

2

Quality Grade , %
Prime

Standard
Yield Grade Distribution2, %

0.08

1

Treatments included: 1) Revalor-IH on d 1 (80 mg trenbalone acetate (TBA)/8 mg estradiol (E2), noncoated, Merck Animal
Health DeSoto, KS) and re-implanted with Revalor-200 on d 101 (200 mg TBA/20 mg E2, noncoated (IH/200), Merck Animal
Health); 2) Revalor-XH on d 1 (200 mg TBA/20 mg E2, partially coated (XH); Merck Animal Health). Revalor-XH contains
four uncoated pellets (80 mg TBA and 8 mg E2) for immediate release and six coated pellets (120 mg TBA and 12 mg E2) to
release approximately 70 to 80 d after implanting.

2

All numbers are expressed as percentages. The yield grade and quality grade values represent the proportion of carcasses within
each group that received a yield and quality grade.
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